Publication number: 20260191835
Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein the variables are defined herein.
Type:
Application
Filed:
November 29, 2023
Publication date:
July 9, 2026
Inventors:
Nikki DASKALAKIS,, Diane Christina GUTTKE, Min Chul KWON, Lucille Angela FERRANTE, Kathryn Elizabeth PACKMAN, Eva Christine PIETSCH, Ulrike PHILIPPAR, Sumia ALI-AHMED, Wei CAI, Johannes Wilhelmus J. THURING, Fabian HULPIA, Xuedong DAI, Ming LI, Xiangjun DENG, Chao LIANG, Alicia Tee Fuay NG, Zhen SUN, Zhigao ZHANG, Samuël Dominique DEMIN, Natalia Nikolaevna DYUBANKOVA, Matthieu Dominique JOUFFROY, Susan LEPRI, Nicolas Freddy J DARVILLE, Vineet PANDE, Wim Bert Griet SCHEPENS, James Patrick EDWARDS, Olivier Alexis Georges QUEROLLE